Email this article Botulinum toxin type A chemodenervation treatment in spastic forms of cerebral palsy
- Authors: Kurenkov A.L.1, Nikitin S.S.2, Artemenko A.R.3, Bursagova B.I.1, Kuzenkova L.M.1, Petrova S.A.1, Klochkova O.A.1, Mamedyarov A.M.1
-
Affiliations:
- Research Center of Child Health, Russian Academy of Medical Sciences, Moscow
- Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow
- I.M. Sechenov First Moscow State Medical University, Moscow
- Issue: Vol 3, No 3 (2013)
- Pages: 40-48
- Section: ORIGINAL REPORTS
- Published: 20.09.2013
- URL: https://nmb.abvpress.ru/jour/article/view/57
- DOI: https://doi.org/10.17650/2222-8721-2013-0-3-40-48
- ID: 57
Cite item
Full Text
Abstract
Cerebral palsy (CP) is one of the most serious outcomes of the perinatal lesion of central nervous system and the most common reason for neurological disability in children. Being the key cause of pathological dynamic stereotypes that frequently result in pathological posture and contractures, spasticity is critically important for CP. The use of botulinum toxin type A (BTA) in complex treatment 2-6 years old CP patients allows significantly to improve motor abilities, help to change the surgical procedure, delay or even avoid some types of surgery. For elder children the use of BTA allows to improve local motor impairment. The treatment of spasticity in CP with BTA is safe (evidence level A) and highly effective (evidence level A). It leads to the positive change of pathological dynamic stereotype, significantly improves gait, decreases muscle tone with Ashworth and Tardeu scales and rises the gross motor function score. Our own experience of onabotulinumtoxinA treatment as a part of complex therapy in 68 patients with spastic forms of CP demonstrates the significant improvement of motor function, most noticeable in younger patients
(early pre-school age) with GMFS I-III.
About the authors
A. L. Kurenkov
Research Center of Child Health, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: alkurenkov@gmail.com
Russian Federation
S. S. Nikitin
Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow
Email: fake@neicon.ru
Russian Federation
A. R. Artemenko
I.M. Sechenov First Moscow State Medical University, Moscow
Email: fake@neicon.ru
Russian Federation
B. I. Bursagova
Research Center of Child Health, Russian Academy of Medical Sciences, Moscow
Email: fake@neicon.ru
Russian Federation
L. M. Kuzenkova
Research Center of Child Health, Russian Academy of Medical Sciences, Moscow
Email: fake@neicon.ru
Russian Federation
S. A. Petrova
Research Center of Child Health, Russian Academy of Medical Sciences, Moscow
Email: fake@neicon.ru
Russian Federation
O. A. Klochkova
Research Center of Child Health, Russian Academy of Medical Sciences, Moscow
Email: fake@neicon.ru
Russian Federation
A. M. Mamedyarov
Research Center of Child Health, Russian Academy of Medical Sciences, Moscow
Email: fake@neicon.ru
Russian Federation
References
Supplementary files
